home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Shareware Overload Trio 2
/
Shareware Overload Trio Volume 2 (Chestnut CD-ROM).ISO
/
dir26
/
med9406d.zip
/
M9460654.TXT
< prev
next >
Wrap
Text File
|
1994-06-25
|
3KB
|
48 lines
Document 0654
DOCN M9460654
TI Long-standing protection of macaques against cell-free HIV-2 with a
HIV-2 iscom vaccine.
DT 9408
AU Putkonen P; Bjorling E; Akerblom L; Thorstensson R; Lovgren K; Benthin
L; Chiodi F; Morein B; Biberfeld G; Norrby E; et al; Department of
Immunology, Swedish Institute for Infectious; Disease Control,
Karolinska Institute, Uppsala.
SO J Acquir Immune Defic Syndr. 1994 Jun;7(6):551-9. Unique Identifier :
AIDSLINE MED/94231459
AB We investigated the capacity of two immunostimulating-complex (iscom)
formulations including inactivated native HIV-2 viral proteins and
selected peptides to induce protective immunity against HIV-2 in a
nonhuman primate. Four cynomolgus monkeys were first immunized with five
i.m. injections of purified detergent-disrupted HIV-2 virions (total
dose, 0.7 mg) in iscoms over a period of 16 months. At months 18 and 20,
all four macaques were given booster immunizations with iscom-coupled
V3-derived synthetic peptides representing a dominating neutralizing
region of HIV-2 gp125. Two weeks after the final dose of vaccine, the
four vaccinated animals, together with four controls, were challenged
i.v. with 10 monkey infectious doses (MID50) of monkey-cell-grown
homologous cell-free virus, HIV-2SBL-6669/H5. After the challenge, the
four control animals became readily infected; however, three of four
vaccinated animals were protected as shown by repeated negative virus
isolations and negative polymerase chain reaction for viral DNA and by
failure to transmit HIV-2 infection with whole blood and lymph node
cells into naive cynomolgus macaques. One of three protected animals
showed an anamnestic antibody response to a dominating antigenic site,
indicating possible limited virus replication. The vaccine-protected
monkeys were subsequently resistant to rechallenge infection at 12, 15,
and 18 months after the first challenge, suggesting that a reasonable
duration of protective immunity had been induced by the vaccine.
DE Amino Acid Sequence Animal *AIDS Vaccines/ADMINISTRATION & DOSAGE
Blotting, Western Disease Models, Animal DNA, Viral/ANALYSIS
Enzyme-Linked Immunosorbent Assay HIV Antibodies/BIOSYNTHESIS HIV
Envelope Protein gp120/CHEMISTRY/IMMUNOLOGY HIV Infections/*PREVENTION
& CONTROL HIV-2/GENETICS/*IMMUNOLOGY/ISOLATION & PURIF Immunization,
Secondary Injections, Intramuscular *ISCOMs/ADMINISTRATION & DOSAGE
Lymph Nodes/CYTOLOGY/MICROBIOLOGY Lymphocytes/MICROBIOLOGY Macaca
fascicularis Molecular Sequence Data Neutralization Tests Peptide
Fragments/CHEMISTRY/IMMUNOLOGY Polymerase Chain Reaction Support,
Non-U.S. Gov't JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).